Shares of Ventyx Biosciences (NASDAQ:VTYX) traded flat on Tuesday, even after the company released promising top-line results ...

Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

In the last year, multiple insiders have substantially increased their holdings of Ventyx Biosciences, Inc. (NASDAQ:VTYX) stock, indicating that insiders' optimism about the company's prospects has ...

Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease.

No acute changes in exploratory PET imaging were observed, consistent with a relatively short, 28-day study Ventyx intends to present the complete dataset at a future medical meeting and to ...

Investing.com -- Ventyx Biosciences (NASDAQ: VTYX) stock was unchanged following the announcement of top-line data from its Phase 2a safety and biomarker trial evaluating VTX3232 in patients with ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials ...

VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025 SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- ...